TY - JOUR
T1 - Effect of the host cell line on the vaccine efficacy of an attenuated porcine reproductive and respiratory syndrome virus
AU - Calzada-Nova, Gabriela
AU - Husmann, Robert J.
AU - Schnitzlein, William M.
AU - Zuckermann, Federico A.
N1 - Funding Information:
This work was supported by the National Pork Board grant #05-200. FAZ is the inventor of patent “Non-Simian Cells for Growth of Porcine Reproductive and Respiratory Syndrome (PRRS) Virus” (US 20110177118, pat. pend.), which was filed by the University of Illinois. FAZ is the founder and chief scientific officer of Aptimmune Biologics, Inc., which is a licensee of the technology described in this patent.
Funding Information:
The authors would like to thank Dr. Mauricio Villamar for his excellent technical assistance and Dr. W Laegreid for providing the nucleotide sequence of genome of the PRRS NADC-20 virus strain. This study was supported by the National Pork Board grant #05-200 .
Copyright:
Copyright 2013 Elsevier B.V., All rights reserved.
PY - 2012/7/15
Y1 - 2012/7/15
N2 - The abilities of the modified-live Prime Pac (PP) strain of porcine reproductive and respiratory syndrome virus (PRRSV), propagated in either traditional simian cells (MARC-145) or in a novel porcine alveolar macrophage cell line (ZMAC), to confer pigs protection against subsequent PRRSV challenge were compared. Eight week-old pigs were injected with PP virus grown in one of the two cell types and then exposed 4 weeks later to the " atypical" PRRSV isolate NADC-20. Control animals were similarly challenged or remained PRRSV-naïve. While the average adjusted body weight (aabw) of the strict control group increased 22% by 10 days post challenge (pc), this value for the non-vaccinated, challenged group dropped 4%. In contrast, prior immunization with PP virus, regardless of its host cell source, ameliorated this effect by affording a >9% rise in aabw. Likewise, nearly equivalent protection was extended to both groups of vaccinates in regards to the temporal elimination of their pc clinical distress and viremia. However, the PP virus propagated in ZMAC cells appeared to be more efficacious since four of the six pigs receiving this biologic cleared the challenge virus from the their lungs by 10 days pc as compared to only one member of the other vaccinated group. Notably, the predominant quasispecies in the ZMAC cell-prepared PP virus stock contained a highly conserved N-glycosylation site at position 184 in its glycoprotein 2 while this entity was underrepresented in the MARC-145 cell grown biologic. Since glycoprotein 2 is involved in infectivity, such additional glycosylation may enhance virus replication in porcine alveolar macrophages.
AB - The abilities of the modified-live Prime Pac (PP) strain of porcine reproductive and respiratory syndrome virus (PRRSV), propagated in either traditional simian cells (MARC-145) or in a novel porcine alveolar macrophage cell line (ZMAC), to confer pigs protection against subsequent PRRSV challenge were compared. Eight week-old pigs were injected with PP virus grown in one of the two cell types and then exposed 4 weeks later to the " atypical" PRRSV isolate NADC-20. Control animals were similarly challenged or remained PRRSV-naïve. While the average adjusted body weight (aabw) of the strict control group increased 22% by 10 days post challenge (pc), this value for the non-vaccinated, challenged group dropped 4%. In contrast, prior immunization with PP virus, regardless of its host cell source, ameliorated this effect by affording a >9% rise in aabw. Likewise, nearly equivalent protection was extended to both groups of vaccinates in regards to the temporal elimination of their pc clinical distress and viremia. However, the PP virus propagated in ZMAC cells appeared to be more efficacious since four of the six pigs receiving this biologic cleared the challenge virus from the their lungs by 10 days pc as compared to only one member of the other vaccinated group. Notably, the predominant quasispecies in the ZMAC cell-prepared PP virus stock contained a highly conserved N-glycosylation site at position 184 in its glycoprotein 2 while this entity was underrepresented in the MARC-145 cell grown biologic. Since glycoprotein 2 is involved in infectivity, such additional glycosylation may enhance virus replication in porcine alveolar macrophages.
KW - Adaptation
KW - Attenuated virus
KW - Cell line
KW - Efficacy
KW - Host cell
KW - Macrophage
KW - PRRSV
KW - Vaccine
KW - Viremia
KW - ZMAC cells
UR - http://www.scopus.com/inward/record.url?scp=84864126195&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84864126195&partnerID=8YFLogxK
U2 - 10.1016/j.vetimm.2012.05.008
DO - 10.1016/j.vetimm.2012.05.008
M3 - Article
C2 - 22648044
AN - SCOPUS:84864126195
SN - 0165-2427
VL - 148
SP - 116
EP - 125
JO - Veterinary Immunology and Immunopathology
JF - Veterinary Immunology and Immunopathology
IS - 1-2
ER -